A Phase 4 interventional study of collagen-povidone solution in Diabetes Complications, sponsored by Instituto Mexicano del Seguro Social. Completed at 1 site in Mexico. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-02.
Sponsored by Instituto Mexicano del Seguro Social · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Diabetes affects 415 million adults globally, leading to hand issues. Povidone collagen shows promise in managing tenosynovitis. A clinical trial was conduced to compared its efficacy in adults over 60. It is shown that the intervention reduces pain, improves functionality, and grip strength with no complications. Collagen povidone holds potential for treating diabetic hand issues.
A randomized clinical trial from January 2022 to January 2023 compared povidone collagen intervention with a placebo in adults aged 60 and above suffering from stenosing tenosynovitis. Participants were randomized into Case (collagen-povidone) and Control (physiological solution) groups. The study evaluated parameters like tenosynovitis, diabetes, pain, functionality, and grip strength.
267 studies on the registry are indexed under Diabetes Complications; 54 are open to participants now.
This study's enrollment of 25 is below the median of 72 across 171 interventional studies indexed under Diabetes Complications.
Browse Diabetes Complications studies →Instituto Mexicano del Seguro Social is the lead sponsor of 126 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: collagen-povidone solution
Drug: collagen-povidone solution
Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group
Also known as: Placebo
Mean evolution time of tenosynovitis
Tenosynovitis should decreased its progression in the experimental group
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Jan 2024, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Mexicano del Seguro Social →